Healthcare >> Analyst Interviews >> May 8, 2002
MARY ANN GRAY has been with the Federated Kaufmann Fund for the
past two years, focusing on both public and private healthcare
investments. Prior to joining the Kaufmann Fund, Dr. Gray was a
sell side Biotechnology Analyst for nine years with Kidder
Peabody; Dillon, Read; and Raymond James. Earlier in her career,
Dr. Gray managed preclinical toxicology studies for the National
Cancer Institute through Battelle Memorial Institute and worked
in a hospital laboratory. She did postdoctoral work at
Northwestern University Medical School and Yale University School
of Medicine. She held scientific positions at Schering-Plough and
NeoRx. Dr. Gray has a PhD in Pharmacology from the University of
Vermont where she focused on novel chemotherapeutic agents for
the treatment of cancer. Profile
the biotech and healthcare life sciences area?
Dr. Gray: Today, in terms of the whole fund, health care is one
of the largest
